Studying a two-step liver surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial looks at a special two-step surgery called ALPPS for people with liver cancer that can't be removed in one operation. The first step helps the liver grow more healthy tissue, and then the second step removes the tumor. The goal is to understand how well this works and how the liver regenerates.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a type of liver cancer (like hepatocellular carcinoma or cholangiocarcinoma) that needs the two-step ALPPS surgery
- Your liver function is good enough for a major surgery (doctors check this with blood tests and scores like Child-Pugh or MELD)
- Your tumors are in multiple parts of the liver or are complex, and your remaining liver after surgery would be too small without the first step
- You do not have cancer that has spread to other parts of your body that can't be removed (except for a few spots in the lungs that can be taken out)
- You are not pregnant or nursing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach: giving two immunotherapy drugs (sintilimab and ipilimumab) along with treatments that block blood flow to the tumor (TACE or ablation) before surgery for liver cancer that is at high risk of coming back. The goal is to see if this combination can shrink the tumor and reduce the chance of recurrence after surgery.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial studies a two-step surgery called ALPPS for people with colorectal cancer that has spread to the liver. It aims to remove more liver tumors safely by growing the remaining liver first, possibly helping more patients become eligible for surgery.
This trial tests a new drug that combines two immune system boosters to shrink liver cancer that has come back after surgery. The goal is to make a second surgery more effective.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This study combines two surgeries—first removing part of the tumor, then a liver transplant—for patients with advanced liver cancer or liver failure. It aims to offer a chance for cure when standard treatments are not possible.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.